1. Home
  2. RYTM vs AQN Comparison

RYTM vs AQN Comparison

Compare RYTM & AQN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • AQN
  • Stock Information
  • Founded
  • RYTM 2008
  • AQN 1988
  • Country
  • RYTM United States
  • AQN Canada
  • Employees
  • RYTM N/A
  • AQN N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • AQN Electric Utilities: Central
  • Sector
  • RYTM Health Care
  • AQN Utilities
  • Exchange
  • RYTM Nasdaq
  • AQN Nasdaq
  • Market Cap
  • RYTM 3.8B
  • AQN 4.1B
  • IPO Year
  • RYTM 2017
  • AQN 1998
  • Fundamental
  • Price
  • RYTM $57.38
  • AQN $5.99
  • Analyst Decision
  • RYTM Strong Buy
  • AQN Hold
  • Analyst Count
  • RYTM 12
  • AQN 6
  • Target Price
  • RYTM $75.42
  • AQN $5.83
  • AVG Volume (30 Days)
  • RYTM 671.0K
  • AQN 11.8M
  • Earning Date
  • RYTM 05-07-2025
  • AQN 05-09-2025
  • Dividend Yield
  • RYTM N/A
  • AQN 5.08%
  • EPS Growth
  • RYTM N/A
  • AQN N/A
  • EPS
  • RYTM N/A
  • AQN N/A
  • Revenue
  • RYTM $136,863,000.00
  • AQN $2,365,738,000.00
  • Revenue This Year
  • RYTM $43.84
  • AQN $4.42
  • Revenue Next Year
  • RYTM $65.62
  • AQN $3.80
  • P/E Ratio
  • RYTM N/A
  • AQN N/A
  • Revenue Growth
  • RYTM 48.88
  • AQN 4.15
  • 52 Week Low
  • RYTM $35.17
  • AQN $4.19
  • 52 Week High
  • RYTM $68.58
  • AQN $6.79
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 43.00
  • AQN 74.90
  • Support Level
  • RYTM $62.69
  • AQN $5.40
  • Resistance Level
  • RYTM $65.53
  • AQN $5.44
  • Average True Range (ATR)
  • RYTM 3.04
  • AQN 0.15
  • MACD
  • RYTM -0.73
  • AQN 0.04
  • Stochastic Oscillator
  • RYTM 1.14
  • AQN 97.06

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About AQN Algonquin Power & Utilities Corp.

Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units consisting of the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.

Share on Social Networks: